Article
Novo Nordisk, citing strong Wegovy demand, doubles 2025 sales target for obesity franchise
Rating:
0.0
Views:
88
Likes:
1
Library:
1
With a supply hitch expected to blow over soon, Novo Nordisk has high hopes for newly minted obesity med Wegovy. | Novo Nordisk is gunning for more than 25 billion Danish krone ($3.72 billion) in obesity sales by 2025, the company said Thursday. Novo had previously aimed to generate around 11.35 billion Danish krone (roughly $1.69 billion) by the middle of the decade, based on earlier weight loss med Saxenda's 2019 sales of 5.7 billion Danish krone ($849 million).
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value